Cargando…
Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy
Autores principales: | Oing, C., Bristow, R.G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040503/ https://www.ncbi.nlm.nih.gov/pubmed/36947986 http://dx.doi.org/10.1016/j.esmoop.2023.101194 |
Ejemplares similares
-
Anthracyclines in the treatment of patients with early breast cancer
por: Guarneri, V., et al.
Publicado: (2022) -
FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer
por: Cervantes, A., et al.
Publicado: (2023) -
Interacting with the Pharmaceutical Industry
por: Hayden, Stephen R.
Publicado: (2003) -
Should Academic Emergency Departments Collaborate in Pharmaceutical Industry-Sponsored Research?: The Dangers of Industry-Funded Research in Emergency Medicine
por: Stone, Susan, et al.
Publicado: (2003) -
Advantages of a Three-year Residency
por: Langdorf, Mark, et al.
Publicado: (2004)